COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06ZVZ
|
|||
Drug Name |
Duvelisib
|
|||
Synonyms |
Duvelisib; 1201438-56-3; IPI-145; INK-1197; UNII-610V23S0JI; IPI 145; 610V23S0JI; INK-1147; Copiktra; IPI-145 (INK1197); Duvelisib [USAN:INN]; IPI145; INK1197; Copiktra (TN); AK145604; Duvelisib (IPI-145, INK1197); Duvel; Duvelisib
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Other Indication | Follicular lymphoma | Approved | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H17ClN6O
|
|||
Canonical SMILES |
CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
|
|||
InChI |
1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1
|
|||
InChIKey |
SJVQHLPISAIATJ-ZDUSSCGKSA-N
|
|||
CAS Number |
CAS 1201438-56-3
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:131169
|
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN PI3-kinase delta (PIK3CD) | Target Info | Inhibitor | [1] |
PI3K inhibition by duvelisib potentially quells aberrant hyperactivtation of the innate immune system, preferentially polarizes macrophages, reduces pulmonary inflammation, and limits viral persistence, which leads to improving outcomes in patients with COVID-19. | ||||
HUMAN PI3-kinase gamma (PIK3CG) | Target Info | Inhibitor | [1] | |
PI3K inhibition by duvelisib potentially quells aberrant hyperactivtation of the innate immune system, preferentially polarizes macrophages, reduces pulmonary inflammation, and limits viral persistence, which leads to improving outcomes in patients with COVID-19. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04372602) Duvelisib to Combat COVID-19. U.S. National Institutes of Health. | |||
2 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 211155 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.